Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the U.S. Food and Drug Administration's approval of its 10 mg/mL strength of Ketamine Hydrochloride Injection, USP, the generic equivalent of JHP Pharmaceuticals' Ketalar(R)CIII.
The details can be read here.
No comments:
Post a Comment